Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL).

Cassin R, Mattiello V, Viltadi M, D'Aliberti D, Piazza R, Gambacorti-Passerini C, Gianelli U, Neri A, Cortelezzi A, Reda G.

Hematol Oncol. 2019 May 18. doi: 10.1002/hon.2638. [Epub ahead of print] No abstract available.


De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways.

Magistroni V, Mauri M, D'Aliberti D, Mezzatesta C, Crespiatico I, Nava M, Fontana D, Sharma N, Parker W, Schreiber A, Yeung D, Pirola A, Readelli S, Massimino L, Wang P, Khandelwal P, Citterio S, Viltadi M, Bombelli S, Rigolio R, Perego R, Boultwood J, Morotti A, Saglio G, Kim DW, Branford S, Gambacorti-Passerini C, Piazza R.

Haematologica. 2019 Sep;104(9):1789-1797. doi: 10.3324/haematol.2017.179937. Epub 2019 Feb 28.


Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells.

Mologni L, Costanza M, Sharma GG, Viltadi M, Massimino L, Citterio S, Purgante S, Raman H, Pirola A, Zucchetti M, Piazza R, Gambacorti-Passerini C.

Neoplasia. 2018 May;20(5):467-477. doi: 10.1016/j.neo.2018.02.009. Epub 2018 Mar 30.


Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.

Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C.

Am J Hematol. 2012 Nov;87(11):E125-8. doi: 10.1002/ajh.23338. Epub 2012 Oct 9.


ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells.

Magistroni V, Mologni L, Sanselicio S, Reid JF, Redaelli S, Piazza R, Viltadi M, Bovo G, Strada G, Grasso M, Gariboldi M, Gambacorti-Passerini C.

PLoS One. 2011;6(11):e28162. doi: 10.1371/journal.pone.0028162. Epub 2011 Nov 30.


Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.

af Gennäs GB, Mologni L, Ahmed S, Rajaratnam M, Marin O, Lindholm N, Viltadi M, Gambacorti-Passerini C, Scapozza L, Yli-Kauhaluoma J.

ChemMedChem. 2011 Sep 5;6(9):1680-92. doi: 10.1002/cmdc.201100168. Epub 2011 Jun 30.


Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib.

Redaelli S, Boschelli F, Perini P, Pirola A, Viltadi M, Gambacorti-Passerini C.

Leukemia. 2010 Jun;24(6):1223-7. doi: 10.1038/leu.2010.79. Epub 2010 May 6. No abstract available.


Supplemental Content

Loading ...
Support Center